The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
Stefan Kasper
Consultant or Advisory Role - Merck Serono
Other Remuneration - Merck Serono
Johannes Meiler
Consultant or Advisory Role - Bayer; Sanofi
Heike Knipp
No relevant relationships to disclose
Thomas Hoehler
No relevant relationships to disclose
Peter Reimer
No relevant relationships to disclose
Tilman Steinmetz
No relevant relationships to disclose
Winfried Berger
No relevant relationships to disclose
Gabriele Linden
No relevant relationships to disclose
Saskia Ting
No relevant relationships to disclose
Peter Markus
No relevant relationships to disclose
Andreas Paul
No relevant relationships to disclose
Martin H. Schuler
Other Remuneration - Merck Serono
Tanja Trarbach
Consultant or Advisory Role - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck Serono; Roche; Sanofi
Honoraria - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck Serono; Roche; Sanofi
Research Funding - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck Serono; Roche; Sanofi
Expert Testimony - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck Serono; Roche; Sanofi
Other Remuneration - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck; Roche; Sanofi